SCHEMBL2198369

SCHEMBL2198369

Cc1nc2ccc(CCc3ccccc3)cn2c1N

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.55
ATP4B P51164 4/20 0.55
NR1H4 Q96RI1 2/20 0.44
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
P2RX3 P56373 1/20 0.40
TLR8 Q9NR97 2/20 0.39
TLR7 Q9NYK1 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
BACE1 P56817 1/20 0.38
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10532171 0.78 ATP4A (0.57) ATP4AATP4BMAOAMAOBMEN1
SCHEMBL2193505 0.76 ATP4A (0.60) ATP4AATP4BNR1H4P2RX3MEN1
SCHEMBL11070613 0.72 ATP4A (0.55) ATP4AATP4BNR1H4TLR8TLR7
SCHEMBL2191092 0.71 ATP4A (1.00) ATP4AATP4BMEN1KMT2AKDM4E
SCHEMBL22145957 0.70 CYP11B1 (0.43) MEN1KMT2AKDM4EALDH1A1
SCHEMBL16563652 0.70 KMT2A (0.54) ATP4AATP4BMEN1KMT2AKDM4E
SCHEMBL10533466 0.70 ATP4A (0.65) ATP4AATP4BTLR8TLR7MEN1
SCHEMBL31309445 0.69 ALPG (0.45) P2RX3MEN1KMT2AKDM4EALDH1A1
SCHEMBL8194463 0.63 ALDH1A1 (0.50) MAOAMAOBKDM4EALDH1A1HPGD
Methylamine SCHEMBL3038332 0.63 MAOA (0.65) MAOAMAOBALDH1A1HPGDCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150086497-A1 Skin Lightening Compositions ELC MAN LLC (US) 2015-03-26 US claimed
EP-2521531-B1 SKIN LIGHTENING COMPOSITIONS ELC MAN LLC (US) 2017-07-12 EP disclosed
US-20170035672-A1 SKIN LIGHTENING COMPOSITIONS ELC MAN LLC (US) 2017-02-09 US disclosed
EP-3103437-A1 SKIN LIGHTENING COMPOSITIONS ELC Management LLC (US) 2016-12-14 EP disclosed
US-9314415-B2 Skin lightening compositions ELC MANAGEMENT LLC (US) 2016-04-19 US disclosed
US-8992897-B2 Skin lightening compositions ELC MANAGEMENT LLC (US) 2015-03-31 US disclosed
US-20150086497-A1 Skin Lightening Compositions ELC MAN LLC (US) 2015-03-26 US disclosed
US-20140212365-A9 SKIN LIGHTENING COMPOSITIONS NIKI YOKO (JP) 2014-07-31 US disclosed
US-20140154190-A1 Skin Lightening Compositions ELC MANAGEMENT, LLC (US) 2014-06-05 US disclosed
US-8722026-B2 Skin lightening compositions ELC MANAGEMENT, LLC (US) 2014-05-13 US disclosed
US-20140112877-A1 SKIN LIGHTENING COMPOSITIONS NIKI YOKO (JP) 2014-04-24 US disclosed
EP-2521531-A2 SKIN LIGHTENING COMPOSITIONS ELC Management LLC (US) 2012-11-14 EP disclosed
US-20110171149-A1 Skin Lightening Compositions ELC MANAGEMENT LLC 2011-07-14 US disclosed
WO-2011085015-A2 SKIN LIGHTENING COMPOSITIONS ELC MANAGEMENT LLC (US) 2011-07-14 WO disclosed
EP-0339071-A1 IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS Aktiebolaget Hässle (SE) 1989-11-02 EP disclosed
WO-1989003833-A1 IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS Aktiebolaget Hässle (SE) 1989-05-05 WO disclosed
EP-0068378-B1 NOVEL IMIDAZO(1,2-A)PYRIDINES AND PYRAZINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1986-03-05 EP disclosed
US-4450164-A ANTIULCER AND ANTISECRETORY AGENTS SCHERING CORPORATION (US) 1984-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171149-A1 Skin Lightening Compositions CUTA, TYR, DSG1 ATP4A 3312/4885ATP4B 3659/4885NR1H4 3950/4885
US-20140212365-A9 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 ATP4A 3312/4885ATP4B 3659/4885NR1H4 3950/4885
US-20170035672-A1 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 ATP4A 3312/4885ATP4B 3659/4885NR1H4 3950/4885
US-20140154190-A1 Skin Lightening Compositions TYR, MC1R, AHR ATP4A 3964/4885ATP4B 4059/4885NR1H4 1305/4885
US-20140112877-A1 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 ATP4A 3312/4885ATP4B 3659/4885NR1H4 3950/4885
US-20150086497-A1 Skin Lightening Compositions CUTA, TYR, DSG1 ATP4A 3312/4885ATP4B 3659/4885NR1H4 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.